Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer

Fig. 5

Identification of potential targets of the METTL3-mediated m6A modification in BC. A Venn diagram showing 498 overlapping genes with differential expression between the GSE763 and GSE87455. B and C GO and KEGG analysis of the overlapping genes. D and E The protein and mRNA levels of METTL3 and CDKN1A in MCF-7 cells with METTL3 knockdown were measured by western blot and qRT-PCR, respectively. F MeRIP with an anti-m6A antibody was performed in MCF-7 cells. The m6A modification on CDKN1A mRNA was reduced upon METTL3 knockdown. G E-cadherin, N-cadherin, Vimentin and GAPDH protein levels were examined by western blot in DOX-treated and control MCF-7 and T47D cell lines after 24 h. H Cell morphologic changes after downregulation of METTL3. I E-cadherin, N-cadherin, Vimentin, METTL3 and GAPDH protein levels were examined by western blot in NC and knockdown METTL3 groups of HR+HER2− BC cells. J E-cadherin, Vimentin, METTL3 and GAPDH protein levels in the vector and overexpression METTL3 groups were examined by western blotting

Back to article page